← Back to Search

Antimicrobial Agent

EVO100 for Gonorrhea (EVOGUARD Trial)

Phase 3
Waitlist Available
Research Sponsored by Evofem Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights

EVOGUARD Trial Summary

This study is evaluating whether a vaginal gel may help prevent the sexual transmission of certain sexually transmitted infections.

Eligible Conditions
  • Gonorrhea
  • Chlamydia
  • Sexually Transmitted Infections

EVOGUARD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Study Successes in the EVO100 and Placebo Treatment Groups
Secondary outcome measures
Evaluate Safety of EVO100: AEs

Side effects data

From 2019 Phase 2 & 3 trial • 860 Patients • NCT03107377
5%
Vulvovaginal Candidiasis
3%
Bacterial Vaginosis
3%
Urinary tract infections
3%
Vaginal Discharge
2%
Vulvovaginal discomfort
100%
80%
60%
40%
20%
0%
Study treatment Arm
EVO100
Placebo

EVOGUARD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: EVO100 gelExperimental Treatment1 Intervention
EVO100 vaginal gel, 5 g
Group II: Placebo gelPlacebo Group1 Intervention
Placebo vaginal gel, 5 g
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EVO100
2017
Completed Phase 3
~2760

Find a Location

Who is running the clinical trial?

Evofem Inc.Lead Sponsor
6 Previous Clinical Trials
6,631 Total Patients Enrolled
Brandi Howard, PhDStudy DirectorEvofem Inc.
Catherine Maher, PhDStudy DirectorEvofem Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
2020. "Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04553068.
~420 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top